WHO 'strongly advises against' use of two COVID-19 antibody therapies: BMJ
Two COVID-19 antibody treatments are no longer recommended by the World Health Organisation because Omicron and its subvariants have likely rendered them obsolete, according to a revised guideline published in the British Medical Journal.
In the same guideline update, the WHO makes a conditional recommendation for the use of the antiviral drug redeliver in patients with severe COVID-19, and a conditional recommendation against its use in patients with the critical disease.
The WHO Guideline Development Group of international experts noted that antibody drugs sotrovimab and basiliximab-imdevimab are not recommended for patients with COVID-19.
These drugs work by binding to the SARS-CoV-2 spike protein -- which helps the virus to enter the cells -- neutralizing its ability to infect.
The ''strong'' recommendation replaces previous conditional recommendations for their use and is based on emerging evidence from laboratory studies that these drugs are not likely to work against currently circulating variants, such as Omicron.
After weighing up all the evidence, the panel judged that almost all well-informed patients would not choose to receive sotrovimab or casirivimab-imdevimab.
These recommendations are based on results from five randomized trials involving 7,643 patients, showing 13 fewer deaths per 1,000 patients with severe COVID-19 taking redeliver, but 34 more deaths per 1,000 patients with critical COVID-19 taking the drug.
These new trial data provided sufficiently trustworthy evidence to demonstrate benefits in patients with severe COVID-19, but not critical COVID-19.
The panel considered the benefits of remdesivir to be modest and of moderate certainty for key outcomes such as mortality and mechanical ventilation, resulting in a conditional recommendation.
WHO also advises that three drugs used to treat arthritis -- the IL-6 receptor blockers tocilizumab or sarilumab and the JAK inhibitor baricitinib -- may now be combined, in addition to corticosteroids, in patients with severe or critical COVID-19.
Interleukin 6 (IL6) plays an important role in immune response while a Janus kinase (JAK) inhibitor is a type of immune-modulating medication.
The latest advice is based on new high-certainty trial evidence confirming a survival benefit for baricitinib with little or no serious adverse events when given in combination with corticosteroids and IL-6 receptor blockers, the panel said.
However, the panel acknowledges some cost and resource implications associated with these drugs, which they said could exacerbate health inequities.
Previously, the WHO has made a strong recommendation for use of nirmatrelvir and ritonavir, and a conditional recommendation for molnupiravir for high-risk patients with non-severe COVID-19.
WHO advises against the use of ivermectin and hydroxychloroquine in patients with COVID-19 regardless of disease severity, the panel added.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)